D
David F. Stroncek
Researcher at National Institutes of Health
Publications - 344
Citations - 10208
David F. Stroncek is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Transplantation & T cell. The author has an hindex of 49, co-authored 308 publications receiving 8622 citations. Previous affiliations of David F. Stroncek include Qatar Airways & Kurume University.
Papers
More filters
Journal ArticleDOI
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno,Irina Maric,Steven Hartman,Jeremy J. Rose,Michael Wang,Norris Lam,Maryalice Stetler-Stevenson,Dalia A. Salem,Constance M. Yuan,Steven Z. Pavletic,Jennifer A. Kanakry,Syed Abbas Ali,Lekha Mikkilineni,Steven A. Feldman,David F. Stroncek,Brenna Hansen,Judith Lawrence,Rashmika Patel,Frances T. Hakim,Ronald E. Gress,James N. Kochenderfer +20 more
TL;DR: CAR-BCMA T cells had substantial activity against heavily treated relapsed/refractory MM and should encourage additional development of CAR T-cell therapies for MM.
Journal ArticleDOI
NAFLD causes selective CD4 + T lymphocyte loss and promotes hepatocarcinogenesis
Chi Ma,Aparna H. Kesarwala,Tobias Eggert,José Medina-Echeverz,David E. Kleiner,Ping Jin,David F. Stroncek,Masaki Terabe,Veena Kapoor,Mei ElGindi,Miaojun Han,Angela M. Thornton,Haibo Zhang,Michèle Egger,Ji Luo,Dean W. Felsher,Daniel W. McVicar,Achim Weber,Mathias Heikenwalder,Mathias Heikenwalder,Tim F. Greten +20 more
TL;DR: It is shown that dysregulation of lipid metabolism in NAFLD causes a selective loss of intrahepatic CD4+ but not CD8+ T lymphocytes, leading to accelerated hepatocarcinogenesis, providing an unexpected link between lipid dysregulation and impaired anti-tumour surveillance.
Journal ArticleDOI
Prostaglandin E2 Enhances Human Cord Blood Stem Cell Xenotransplants and Shows Long-Term Safety in Preclinical Nonhuman Primate Transplant Models
Wolfram Goessling,Robyn S. Allen,Xiao Guan,Ping Jin,Naoya Uchida,Michael C Dovey,James M. Harris,Mark E. Metzger,Aylin C. Bonifacino,David F. Stroncek,Joseph Stegner,Myriam Armant,Thorsten M. Schlaeger,John F. Tisdale,Leonard I. Zon,Leonard I. Zon,Leonard I. Zon,Robert E. Donahue,Trista E. North,Trista E. North +19 more
TL;DR: Preclinical analyses indicated that dmPGE2 mediates conserved responses in HSCs from human and nonhuman primates and provided sufficient preclinical information to support proceeding to an FDA-approved phase 1 clinical trial.
Journal ArticleDOI
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.
Marianna Sabatino,Jinhui Hu,Michele Sommariva,Michele Sommariva,Sanjivan Gautam,Vicki Fellowes,James D. Hocker,Sean C. Dougherty,Haiying Qin,Christopher A. Klebanoff,Terry J. Fry,Ronald E. Gress,James N. Kochenderfer,David F. Stroncek,Yun Ji,Luca Gattinoni +15 more
TL;DR: This clinical-grade platform provides the basis for a phase 1 trial evaluating the activity of CD19-CAR-modified CD8(+) TSCM in patients with B-cell malignancies refractory to prior allogeneic hematopoietic stem cell transplantation.
Journal ArticleDOI
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah,Steven L. Highfill,Haneen Shalabi,Bonnie Yates,Jianjian Jin,Pamela L. Wolters,Amanda K. Ombrello,Seth M. Steinberg,Staci Martin,Cindy Delbrook,Leah Hoffman,Lauren Little,Anusha Ponduri,Haiying Qin,Haris Qureshi,Alina Dulau-Florea,Dalia Salem,Hao-Wei Wang,Constance M. Yuan,Maryalice Stetler-Stevenson,Sandhya R. Panch,Minh Tran,Crystal L. Mackall,Crystal L. Mackall,David F. Stroncek,Terry J. Fry,Terry J. Fry +26 more
TL;DR: The remission induction rate supports further development of CD22 CAR T cells as a therapeutic option in patients resistant to CD19-targeted immunotherapy, and novel information on the impact of manufacturing changes on clinical outcomes is provided.